Medicus Pharma reported an 80% overall response rate (ORR) in Phase 2 data for SkinJect. Dr. Babar Rao, a key opinion leader, validated that the outcomes are clinically meaningful for treating non-melanoma skin cancer. The treatment could potentially allow the majority of lesions to avoid immediate surgery.
